Rabies Vaccine Response End Point Titer
Rabies Antibody (Immune Status Testing)
Test Codes
EPIC: LAB1232247, Beaker: Rabies Titer, Quest: 5789
Department
Send Outs
Specimen Collection Criteria
Collect (preferred specimen): One Gold-top SST tube.
Also acceptable: One plain Red-top tube.
Physician Office/Draw Specimen Preparation
Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F).
Preparation for Courier Transport
Transport: 1.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 1.0 mL)
Rejection Criteria
- Gross hemolysis.
- Grossly lipemic.
- Specimens not collected and processed as indicated.
In-Lab Processing
Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and refrigerate (2-8°C or 36-46°F).
Transport: 1.0 mL serum, refrigerated (2-8°C or 36-46°F). (Minimum: 1.0 mL)
Storage
Specimen Stability for Testing:
Room Temperature (20-26°C or 68-78.8°F): Unacceptable
Refrigerated (2-8°C or 36-46°F): 10 days
Frozen (-20°C/-4°F or below): 30 days
Specimen Storage in Department Prior to Disposal:
Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.
Laboratory
Sent to Quest Diagnostics, Wood Dale, IL.
Performed
Varies.
Results available in 3-4 weeks.
Test Methodology
Rapid Fluorescent FOCI Inhibition Test (RFFIT)
Interpretation
By report.
Clinical Utility
Rabies Vaccine Response End
Point Titer – What is the RFFIT??
The acronym RFFIT stands for Rapid Fluorescent
Focus Inhibition Test. The test measures the ability of antibodies that may be
present in a sample to neutralize and block rabies virus from infecting the
cells used in the test. These antibodies are called rabies virus neutralizing
antibodies (RVNA). In the test, serum (the non-cellular portion of a blood
sample) is first diluted fivefold (1 part serum in 4 parts diluent). Further
(serial fivefold) dilutions are performed, each of which contain less and less
of the sample. The serum dilutions are mixed with a standard amount of live
rabies virus and incubated. If RVNA are present in the sample, they will bind
to the virus. Tissue culture cells are then added and incubated with the test
sample and virus. Whatever rabies virus that may not have been neutralized by
the antibody in the sample will then infect the cells. These foci of infection
in the cells can then be seen under the fluorescent microscope. If there are a
lot of infected cells, there is very little antibody; conversely, if antibodies
are high, the cells will have very little evidence of infection. The endpoint
titer is calculated from the percent of virus-infected areas observed within
the wells containing the various dilutions of the sample on the slide.
What
does your result tell you?
The RFFIT result can be reported in either a
titer which is a ratio (e.g., 1:50) or as a standardized concentration
represented as international units (IU) per mL of serum (e.g., 0.5 IU/mL). The
IU value is calculated from the titer by comparing it against a standard
reference serum. We use the following formula: sample titer divided by the
reference serum titer, multiplied by the IU/mL value of the reference serum.
Because the RFFIT test is a biological system
using live cells, infectious virus, and antibodies, the reference serum can
vary in titer level for each batch of testing (within an established acceptable
range). Therefore the calculation of IU/mL depends on the titer of the
reference serum measured in the batch tested. In general, you can take the
titer value divided by 100 to get a rough estimate of the IU/mL value. To
obtain the exact value you must use the calculation with the reference serum
titer value that resulted from that batch of tests.
According to World Health Organization
guidelines, a rabies antibody level of greater than or equal to 0.5 IU/mL
demonstrates an adequate response to vaccination (1). If the level falls below
this value, a booster dose of rabies vaccine may be recommended for people who
are at frequent risk of rabies virus exposure. In contrast, the ACIP guidelines
state that evidence of complete neutralization at a serum dilution of 1:5 in
RFFIT testing (corresponding to 0.1-0.2 IU/mL in our laboratory) is considered
an adequate response to rabies vaccination (2). The lowest antibody level that
can be accurately and precisely measured by the RFFIT in our laboratory is 0.1
IU/mL; below this level, there is uncertainty as to the specificity of the
result. Because the ACIP level is close to the assay threshold, the level of
0.5 IU/mL is more conservative for guiding human vaccination decisions and
applicable in most situations.
Points that should be considered as to whether
a person should receive a booster dose of rabies vaccine when their antibody
level falls below 0.5 IU/mL are:
- Anticipated risk of exposure (i.e., routinely
handling sick animals or rabies reservoir species in enzootic areas).
- Length of time until the next antibody
measurement.
- Previous rabies antibody levels and the probability
of decay to low or undetectable levels in the intervening period.
- Individual health status (consider
immunocompromising conditions or a history of poor vaccine response).
- Timely access to vaccine and administration
should a potential exposure occur.
Contacts
Send Outs Laboratory – RO
248-551-9045
Name: Send Outs Laboratory – RO
Location:
Phone: 248-551-9045
Last Updated
12/19/2025
Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.